Multifunctional vaccines in cancer: The 'triad' approach

Expert Review of Vaccines

Volumn 10, Issue 6, 2011, Pages 713-715

  Nemunaitis, John ^a,b,c  

^a Mary Crowley Cancer Research Centers   (United States)

^b TEXAS ONCOLOGY   (United States)

^c MEDICAL CITY DALLAS HOSPITAL   (United States)

Author keywords

cancer; gene; multifunctional; vaccine

Indexed keywords

CANCER VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IPILIMUMAB; LUCANIX; LUCANIX VACCINE; ONCOVEX; PROVENGE; TAG VACCINE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER CONTROL; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; DENDRITIC CELL; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; IMMUNE SYSTEM; LUNG NON SMALL CELL CANCER; MELANOMA; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; TUMOR IMMUNITY; TUMOR REGRESSION;

BIOMEDICAL RESEARCH; CANCER VACCINES; DRUG APPROVAL; HUMANS; NEOPLASMS; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 79959540821     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.11.78     Document Type: Review

References (19)

1. Gilboa E, Nair SK, Lyerly HK. Immunotherapy of cancer with dendritic-cell-based vaccines. Cancer Immunol. Immunother. 46(2), 82-87 (1998 (Pubitemid 28177482)
2. Timmerman JM, Levy R. Dendritic cell vaccines for cancer immunotherapy. Annu. Rev. Med. 50, 507-529 (1999 (Pubitemid 29117080)
3. Cranmer LD, Trevor KT, Hersh EM. Clinical applications of dendritic cell vaccination in the treatment of cancer. Cancer Immunol. Immunother. 53(4), 275-306 (2004 (Pubitemid 38392306)
4. Hirschowitz EA, Foody T, Kryscio R, Dickson L, Sturgill J, Yannelli J. Autologous dendritic cell vaccines for non-small-cell lung cancer. J. Clin. Oncol. 22(14), 2808-2815 (2004 (Pubitemid 41079898)
5. Banchereau J, Briere F, Caux C et al. Immunobiology of dendritic cells. Annu. Rev. Immunol. 18, 767-811 (2000 (Pubitemid 30365397)
6. Pulendran B, Smith JL, Caspary G et al. Distinct dendritic cell subsets differentially regulate the class of immune response in vivo. Proc. Natl Acad. Sci. USA 96(3), 1036-1041 (1999
7. Woo EY, Yeh H, Chu CS et al. Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J. Immunol. 168(9), 4272-4276 (2002 (Pubitemid 34441324)
8. Woo EY, Chu CS, Goletz TJ et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 61(12), 4766-4772 (2001 (Pubitemid 32691889)
9. Schwartz RH. Models of T cell anergy: is there a common molecular mechanism? J. Exp. Med. 184(1), 1-8 (1996 (Pubitemid 26247209)
10. Lombardi G, Sidhu S, Batchelor R, Lechler R. Anergic T cells as suppressor cells in vitro. Science 264(5165), 1587-1589 (1994 (Pubitemid 24227713)
11. Ruffini PA, Rivoltini L, Silvani A, Boiardi A, Parmiani G. Factors, including transforming growth factor b, released in the glioblastoma residual cavity, impair activity of adherent lymphokine-activated killer cells. Cancer Immunol. Immunother. 36(6), 409-416 (1993 (Pubitemid 23146829)
12. Rook AH, Kehrl JH, Wakefield LM et al. Effects of transforming growth factor b on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. J. Immunol. 136(10), 3916-3920 (1986 (Pubitemid 16122096)
13. Tsunawaki S, Sporn M, Ding A, Nathan C. Deactivation of macrophages by transforming growth factor-b. Nature 334(6179), 260-262 (1988
14. Hirte HW, Clark DA, O'Connell G, Rusthoven J, Mazurka J. Reversal of suppression of lymphokine-activated killer cells by transforming growth factor-b in ovarian carcinoma ascitic fluid requires interleukin-2 combined with anti-CD3 antibody. Cell. Immunol. 142(1), 207-216 (1992
15. Nemunaitis J, Sterman D, Jablons D et al. Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. J. Natl Cancer Inst. 96(4), 326-331 (2004 (Pubitemid 38256277)
16. Nemunaitis J, Dillman RO, Schwarzenberger PO et al. Phase II study of belagenpumatucel-L, a transforming growth factor b-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J. Clin. Oncol. 24(29), 4721-4730 (2006 (Pubitemid 46630936)
17. Senzer NN, Kaufman HL, Amatruda T et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J. Clin. Oncol. 27(34), 5763-5771 (2009
18. Olivares J, Kumar P, Yu Y et al. Phase I trial of TGF-{b}2 antisense GM-CSF gene-modified autologous tumor cell (TAG) vaccine. Clin. Cancer Res. 17(1), 183-192 (2011
19. Maples PB, Kumar P, Yu Y et al. FANG vaccine: autologous tumor vaccine genetically modified to express GM-CSF and block production of furin. BioProcessing Journal 8(4), 4-14 (2010